Angiotensin Blockade in Coarctation of the Aorta

Artur B. Ribeiro; Lawrence R. Krakoff

doi:10.1056/NEJM197607152950307

Angiotensin Blockade in Coarctation of the Aorta

Artur B. Ribeiro
, Lawrence R. Krakoff

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Coarctation of the thoracic aorta is a well established cause of arterial hypertension. Participation of the renin-angiotensin system in the hypertension due to coarctation of the aorta has been suggested¹^,² and denied.³ ⁴ ⁵ The availability of specific peptide antagonists of the renin-angiotensin system for clinical investigation permits direct assessment of the role of the renin-angiotensin system in clinical hypertension.⁶ ⁷ ⁸ The use of a competitive inhibitor of angiotensin II action, sarala¹ ⁸ angiotensin II (saralasin), has been successful in demonstrating the participation of the renin-angiotensin system in malignant and renovascular hypertension.⁶^,⁷ We present observations on the use of saralasin in two patients with.

Original language	English
Pages (from-to)	148-150
Number of pages	3
Journal	New England Journal of Medicine
Volume	295
Issue number	3
DOIs	https://doi.org/10.1056/NEJM197607152950307
State	Published - 15 Jul 1976
Externally published	Yes

Access to Document

10.1056/NEJM197607152950307

Cite this

@article{3ca0d61b8040409f88393a7422f5955e,

title = "Angiotensin Blockade in Coarctation of the Aorta",

abstract = "Coarctation of the thoracic aorta is a well established cause of arterial hypertension. Participation of the renin-angiotensin system in the hypertension due to coarctation of the aorta has been suggested1,2 and denied.3 4 5 The availability of specific peptide antagonists of the renin-angiotensin system for clinical investigation permits direct assessment of the role of the renin-angiotensin system in clinical hypertension.6 7 8 The use of a competitive inhibitor of angiotensin II action, sarala1 8 angiotensin II (saralasin), has been successful in demonstrating the participation of the renin-angiotensin system in malignant and renovascular hypertension.6,7 We present observations on the use of saralasin in two patients with.",

author = "Ribeiro, \{Artur B.\} and Krakoff, \{Lawrence R.\}",

year = "1976",

month = jul,

day = "15",

doi = "10.1056/NEJM197607152950307",

language = "English",

volume = "295",

pages = "148--150",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "3",

}

TY - JOUR

T1 - Angiotensin Blockade in Coarctation of the Aorta

AU - Ribeiro, Artur B.

AU - Krakoff, Lawrence R.

PY - 1976/7/15

Y1 - 1976/7/15

N2 - Coarctation of the thoracic aorta is a well established cause of arterial hypertension. Participation of the renin-angiotensin system in the hypertension due to coarctation of the aorta has been suggested1,2 and denied.3 4 5 The availability of specific peptide antagonists of the renin-angiotensin system for clinical investigation permits direct assessment of the role of the renin-angiotensin system in clinical hypertension.6 7 8 The use of a competitive inhibitor of angiotensin II action, sarala1 8 angiotensin II (saralasin), has been successful in demonstrating the participation of the renin-angiotensin system in malignant and renovascular hypertension.6,7 We present observations on the use of saralasin in two patients with.

AB - Coarctation of the thoracic aorta is a well established cause of arterial hypertension. Participation of the renin-angiotensin system in the hypertension due to coarctation of the aorta has been suggested1,2 and denied.3 4 5 The availability of specific peptide antagonists of the renin-angiotensin system for clinical investigation permits direct assessment of the role of the renin-angiotensin system in clinical hypertension.6 7 8 The use of a competitive inhibitor of angiotensin II action, sarala1 8 angiotensin II (saralasin), has been successful in demonstrating the participation of the renin-angiotensin system in malignant and renovascular hypertension.6,7 We present observations on the use of saralasin in two patients with.

UR - https://www.scopus.com/pages/publications/0017170238

U2 - 10.1056/NEJM197607152950307

DO - 10.1056/NEJM197607152950307

M3 - Article

C2 - 1272332

AN - SCOPUS:0017170238

SN - 0028-4793

VL - 295

SP - 148

EP - 150

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 3

ER -

Angiotensin Blockade in Coarctation of the Aorta

Abstract

Access to Document

Fingerprint

Cite this